Name | Lutikizumab |
---|
Description | Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis[1]. |
---|---|
Related Catalog | |
In Vitro | ABT-981 可同时结合人 IL-α 和 IL-1β 分子[1]。 ABT-981 对 IL-α 和 IL-1β 表现出高度特异性的结合作用相比于其他 IL-1 家族成员[1]。 |
In Vivo | Lutikizumab (0.0001-1 mg/kg,腹腔注射,1 次) 对 IL-1α 和 IL-1β 诱导的 IL-6 产生有效抑制作用[1]。 Animal Model: Female C57/BL6 mice with IL-1α and IL-1β injection[1] Dosage: 0.0001-1 mg/kg Administration: Intraperitoneal injection, 0.0001-1 mg/kg, once Result: Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1α and IL-1β. |
References |
No Any Chemical & Physical Properties |